Masaaki Mori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8200888/publications.pdf

Version: 2024-02-01

304701 233409 2,359 113 22 45 citations h-index g-index papers 116 116 116 2536 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritisâ \in "secondary publication. Modern Rheumatology, 2023, 33, 21-35.	1.8	35
2	Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 96-104.	1.8	13
3	Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. Modern Rheumatology, 2022, 32, 121-126.	1.8	O
4	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 74-86.	1.8	11
5	Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 313-322.	1.8	7
6	Patients' perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. Modern Rheumatology, 2022, 32, 307-312.	1.8	6
7	Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology, 2022, 61, 1222-1227.	1.9	32
8	Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 296-306.	1.8	5
9	A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan. Modern Rheumatology, 2022, 32, 960-967.	1.8	6
10	Clinical practice guidance for childhood-onset systemic lupus erythematosusâ€"secondary publication. Modern Rheumatology, 2022, 32, 239-247.	1.8	1
11	Transitioning from paediatric to adult rheumatological healthcare: English summary of the Japanese Transition Support Guide. Modern Rheumatology, 2022, 32, 248-255.	1.8	1
12	Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties. Journal of Dermatology, 2022, 49, 441-447.	1.2	3
13	Septic arthritis of the pubic symphysis in a patient with SLE. Pediatrics International, 2022, 64, .	0.5	O
14	A girl with hearing loss, dizziness, hypertension, and pyelonephritis with ureteral edema: Questions. Pediatric Nephrology, 2022, , .	1.7	0
15	A girl with hearing loss, dizziness, hypertension, and pyelonephritis with ureteral edema: Answers. Pediatric Nephrology, 2022, , .	1.7	O
16	Ankylosing spondylitis, Crohn's disease, and myelodysplasia in an adolescent. Pediatrics International, 2022, 64, .	0.5	0
17	Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation. Annals of the Rheumatic Diseases, 2021, 80, 542-543.	0.9	4
18	Hospitalisations due to respiratory syncytial virus infection in children with Down syndrome before and after palivizumab recommendation in Japan. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 1299-1306.	1.5	5

#	Article	IF	CITATIONS
19	External validation of the EULAR/ACR idiopathic inflammatory myopathies classification criteria withÂa Japanese paediatric cohort. Rheumatology, 2021, 60, 802-808.	1.9	O
20	Questionnaire survey on transitional care for patients with juvenile idiopathic arthritis (JIA) and families. Modern Rheumatology, 2021, 31, 691-696.	1.8	7
21	Clinical practice guidance for Sjögren's syndrome in pediatric patients (2018) – summarized and updated. Modern Rheumatology, 2021, 31, 283-293.	1.8	6
22	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Modern Rheumatology, 2021, 31, 29-33.	1.8	49
23	Childhoodâ€onset systemic lupus erythematosus with trisomy X and the increased risk for bone complications: a case report. Pediatric Rheumatology, 2021, 19, 20.	2.1	3
24	Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. BMC Pediatrics, 2021, 21, 106.	1.7	1
25	Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology, 2021, 60, 4821-4831.	1.9	12
26	The Benefits and Respective Side-Effects of PE Therapy for Intractable Kawasaki Disease. Journal of Clinical Medicine, 2021, 10, 1062.	2.4	0
27	Hemophagocytic lymphohistiocytosis associated with primary cutaneous gammaâ€delta Tâ€cell lymphoma presenting with subcutaneous panniculitis in a 12â€yearâ€old girl. Pediatric Blood and Cancer, 2021, 68, e29035.	1.5	1
28	Giant Iliopsoas Bursitis in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2021, 73, 1328-1328.	5.6	0
29	Multifocal and extrapulmonary tuberculosis due to immunosuppressants. Pediatrics International, 2021, 63, 1117-1119.	0.5	3
30	Pediatric Dual-Energy X-Ray Absorptiometry in Japan: A Proposal for Shared Access to Equipment. Journal of Nippon Medical School, 2021, 88, 296-300.	0.9	0
31	Concurrent lupus enteritis and cystitis. Pediatrics International, 2021, 63, 1142-1143.	0.5	1
32	Leucine-rich alpha-2-glycoprotein 1 and angiotensinogen as diagnostic biomarkers for Kawasaki disease. PLoS ONE, 2021, 16, e0257138.	2.5	5
33	Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open, 2021, 7, e001747.	3.8	10
34	Tacrolimus as an alternative treatment for patients with juvenile idiopathic arthritis. Modern Rheumatology, 2021, , .	1.8	0
35	Disease activity, treatment and long-term prognosis of adult juvenile idiopathic arthritis patients compared with rheumatoid arthritis patients. Modern Rheumatology, 2020, 30, 78-84.	1.8	10
36	Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2020, 18, 2.	2.1	36

#	Article	IF	Citations
37	What are the main revised points in the 6th diagnostic guidelines for Kawasaki disease?. Pediatrics International, 2020, 62, 1133-1134.	0.5	1
38	Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Modern Rheumatology, 2020, 30, 411-423.	1.8	31
39	Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases. Pediatric Rheumatology, 2020, 18, 26.	2.1	6
40	Immune thrombocytopenic purpura risk by live, inactivated and simultaneous vaccinations among Japanese adults, children and infants: a matched case–control study. International Journal of Hematology, 2020, 112, 105-114.	1.6	12
41	Refractory secondary thrombotic microangiopathy with kidney injury associated with systemic lupus erythematosus in a pediatric patient. CEN Case Reports, 2020, 9, 301-307.	0.9	0
42	Liver cirrhosis in a child associated with Castleman's disease: A case report. World Journal of Clinical Cases, 2020, 8, 1656-1665.	0.8	3
43	The Working Group for Revision of "Guidelines for the Use of Palivizumab in Japan― A Committee Report. Pediatrics International, 2020, 62, 1223-1229.	0.5	3
44	Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. Modern Rheumatology, 2019, 29, 41-59.	1.8	25
45	Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. Modern Rheumatology, 2019, 29, 808-813.	1.8	10
46	Mycophenolate mofetil and prednisolone for cerebral sinus venous thrombosis with Behcet's disease. Pediatrics International, 2019, 61, 920-922.	0.5	5
47	A Nonsense SMAD3 Mutation in a Girl with Familial Thoracic Aortic Aneurysm and Dissection without Joint Abnormality. Cardiology, 2019, 144, 53-59.	1.4	0
48	Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Pediatric Rheumatology, 2019, 17, 17.	2.1	8
49	In order to identify immunocompromised patients, what should general pediatricians do first?. Pediatrics International, 2019, 61, 4-4.	0.5	0
50	Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ). Pediatric Rheumatology, 2019, 17, 15.	2.1	23
51	AB1027â€DEVELOPMENT OF A NOVEL DIAGNOSTIC METHOD FOR ATYPICAL AND TREATMENT-REFRACTORY KAWASAKI DISEASE USING NEWLY IDENTIFIED PROTEINS AS BIOMARKERS., 2019, , .		0
52	Intestinal Behçet disease associated with myelodysplastic syndrome accompanying trisomy 8 successfully treated with abdominal surgery followed by hematopoietic stem cell transplantation. Medicine (United States), 2019, 98, e17979.	1.0	11
53	Pharmacokinetics of mycophenolate mofetil in juvenile patients with autoimmune diseases. Modern Rheumatology, 2019, 29, 1002-1006.	1.8	2
54	Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Scientific Reports, 2018, 8, 1994.	3.3	54

#	Article	IF	CITATIONS
55	Survey of the awareness of adult rheumatologists regarding transitional care for patients with juvenile idiopathic arthritis in Japan. Modern Rheumatology, 2018, 28, 981-985.	1.8	11
56	Proposal for the development of biologics in pediatric rheumatology. Pediatrics International, 2018, 60, 108-114.	0.5	1
57	Vitamin B1 Deficiency Related to Excessive Soft Drink Consumption in Japan. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 838-842.	1.8	10
58	Mycophenolate mofetil therapy for two cases of antiphospholipid antibody-associated chorea. Modern Rheumatology, 2018, 28, 709-711.	1.8	6
59	Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance. Modern Rheumatology, 2018, 28, 101-107.	1.8	2
60	Validation of Classification Criteria of Macrophage Activation Syndrome in Japanese Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2018, 70, 1412-1415.	3.4	15
61	Characteristics and outcome of intractable vasculitis syndrome in children: Nation-wide survey in Japan. Modern Rheumatology, 2018, 28, 697-702.	1.8	3
62	Pediatric rheumatic diseases: a review regarding the improvement of long-term prognosis and the transition to adults. Immunological Medicine, 2018, 41, 2-5.	2.6	8
63	Hypercytokinemia with hemophagocytic syndrome due to human metapneumovirus. Pediatrics International, 2018, 60, 974-976.	0.5	1
64	Parental awareness of young children's pattern of ionic beverage consumption. Pediatrics International, 2018, 60, 969-973.	0.5	1
65	Fever Responses Are Enhanced with Advancing Age during Respiratory Syncytial Virus Infection among Children under 24 Months Old. Tohoku Journal of Experimental Medicine, 2018, 245, 217-222.	1.2	8
66	Safety and efficacy of DTaP-IPV vaccine use in healthcare workers for prevention of pertussis. Vaccine, 2018, 36, 5935-5939.	3.8	1
67	Attitudes of pediatricians toward Children's consumption of ionic beverages. BMC Pediatrics, 2018, 18, 176.	1.7	0
68	Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection. EBioMedicine, 2017, 16, 124-135.	6.1	27
69	Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis. Scientific Reports, 2017, 7, 43732.	3.3	48
70	Placental Transfer of Canakinumab in a Patient with Muckle-Wells Syndrome. Journal of Clinical Immunology, 2017, 37, 339-341.	3.8	17
71	Oseltamivir use and severe abnormal behavior in Japanese children and adolescents with influenza: Is a self-controlled case series study applicable?. Vaccine, 2017, 35, 4817-4824.	3.8	9
72	Usefulness of the Combination of Tuberculin Skin Test and Interferon-Gamma Release Assay in Diagnosing Children with Tuberculosis. Tohoku Journal of Experimental Medicine, 2017, 243, 205-210.	1,2	3

#	Article	IF	CITATIONS
73	Usefulness of two interferonâ $\hat{\epsilon l}^3$ release assays for rheumatic disease. Pediatrics International, 2016, 58, 347-352.	0.5	7
74	Characteristics of FDG-PET findings in the diagnosis of systemic juvenile idiopathic arthritis. Modern Rheumatology, 2016, 26, 362-367.	1.8	5
75	Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children. Pediatric Nephrology, 2016, 31, 425-434.	1.7	33
76	Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch Regimens in Immunocompromised Japanese Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 1004-1013.	3.2	22
77	Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis. Journal of Infection and Chemotherapy, 2015, 21, 421-426.	1.7	4
78	Skin thickness in young infants and adolescents: Applications for intradermal vaccination. Vaccine, 2015, 33, 3384-3391.	3.8	16
79	Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. Modern Rheumatology, 2015, 25, 854-857.	1.8	11
80	Discrepancy Between Clinical and Radiological Responses to Tocilizumab Treatment in Patients with Systemic-onset Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 1171-1177.	2.0	22
81	Infliximab Plus Plasma Exchange Rescue Therapy in Kawasaki Disease. Journal of Pediatrics, 2014, 164, 1128-1132.e1.	1.8	50
82	Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome. Journal of Infection and Chemotherapy, 2014, 20, 455-459.	1.7	29
83	Palivizumab Use In Japanese Infants And Children With Immunocompromised Conditions. Pediatric Infectious Disease Journal, 2014, 33, 1183-1185.	2.0	15
84	A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients. Journal of Infection and Chemotherapy, 2013, 19, 174-179.	1.7	4
85	Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan. Journal of Infection and Chemotherapy, 2013, 19, 946-950.	1.7	4
86	Clinical analysis of 50 children with juvenile dermatomyositis. Modern Rheumatology, 2013, 23, 311-317.	1.8	23
87	Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis. Modern Rheumatology, 2013, 23, 667-673.	1.8	8
88	Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan. Modern Rheumatology, 2012, 22, 491-497.	1.8	5
89	Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan. Modern Rheumatology, 2012, 22, 720-726.	1.8	11
90	Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clinical Rheumatology, 2012, 31, 1713-1721.	2.2	55

#	Article	IF	Citations
91	Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Modern Rheumatology, 2012, 22, 109-115.	1.8	56
92	Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-label Case Series. Journal of Rheumatology, 2012, 39, 864-867.	2.0	72
93	Longâ€term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatrics International, 2012, 54, 99-103.	0.5	63
94	Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan. Modern Rheumatology, 2012, 22, 720-726.	1.8	9
95	Guidance on using tocilizumab for juvenile idiopathic arthritis. Modern Rheumatology, 2011, 21, 563-571.	1.8	9
96	Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic disease in general. Modern Rheumatology, 2011, 21, 449-457.	1.8	3
97	Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials. Modern Rheumatology, 2011, 21, 572-578.	1.8	11
98	Superior mesenteric artery syndrome: Risk factor for duodenal involvement in Henoch–Schönlein purpura. Pediatrics International, 2011, 53, 630-633.	0.5	4
99	Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. Journal of Infection and Chemotherapy, 2011, 17, 254-263.	1.7	30
100	Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic disease in general. Modern Rheumatology, 2011, 21, 449-457.	1.8	2
101	Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. Modern Rheumatology, 2010, 20, 107-113.	1.8	7
102	Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Modern Rheumatology, 2009, 19, 1-11.	1.8	9
103	Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet, The, 2008, 371, 998-1006.	13.7	734
104	Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007). Modern Rheumatology, 2007, 17, 353-363.	1.8	19
105	Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Modern Rheumatology, 2004, 14, 43-47.	1.8	69
106	Plasma exchange for refractory Kawasaki disease. European Journal of Pediatrics, 2004, 163, 263-264.	2.7	68
107	Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Modern Rheumatology, 2004, 14, 361-366.	1.8	32
108	Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis. Modern Rheumatology, 2004, 14, 12-17.	1.8	17

#	Article	IF	CITATIONS
109	Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Modern Rheumatology, 2004, 14, 43-47.	1.8	39
110	Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Modern Rheumatology, 2004, 14, 361-366.	1.8	18
111	Predictors of coronary artery lesions after intravenous \hat{l}^3 -globulin treatment in Kawasaki disease. Journal of Pediatrics, 2000, 137, 177-180.	1.8	108
112	Successful Treatment of Onychomycosis with Fluconazole in Two Patients with Hyperimmunoglobulin E Syndrome. Pediatric Dermatology, 1996, 13, 493-495.	0.9	17
113	Atrophic Autoimmune Thyroiditis Complicated with Systemic Lupus Erythematosus. Modern Rheumatology Case Reports, 0, , .	0.7	0